close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

38.38 -0.15 (-0.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
$122M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed mixed on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 32 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 64 companies achieved new lows for the year. 
Via Benzinga
News headline image
$10M Bet On GameStop? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Earnings Outlook For Royalty Pharma ↗
 
Via Benzinga
News headline image
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 129 stocks made new 52-week lows. 
Via Benzinga
News headline image
Preview: Royalty Pharma's Earnings ↗
 
Via Benzinga
Ominous Death Cross Forms On Royalty Pharma's Chart ↗
 
Via Benzinga
News headline image
$12.5M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance ↗
 
Via Benzinga
News headline image
Royalty Pharma Reports First Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Second Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
From PureTech Health plc
Via Business Wire
News headline image
Royalty Pharma Raises Full Year 2023 Guidance
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday, 79 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Insiders Selling TransMedics Group And 2 Other Stocks ↗
The Nasdaq 100 closed higher by around 0.7% on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023 ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Royalty Pharma Reports Q4 and Full Year 2022 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
News headline image
Five Best And Worst Performing Healthcare Stocks In December 2022 ↗
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
News headline image
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today